Long-term outcomes of additional surgery after endoscopic resection versus primary surgery for T1 colorectal cancer
Yuzuru Tamaru,Toshio Kuwai,Yoshiki Kajiwara,Shiro Oka,Shoichi Saito,Yosuke Fukunaga,Hiroshi Kawachi,Manabu Takamatsu,Kinichi Hotta,Hiroaki Ikematsu,Motohiro Kojima,Yutaka Saito,Yukihide Kanemitsu,Masayoshi Yamada,Shigeki Sekine,Shinji Tanaka,Shinji Nagata,Takahiro Nakamura,Kazutaka Yamada,Maki Konno,Soichiro Ishihara,Yusuke Saitoh,Kenji Matsuda,Kazutomo Togashi,Koji Komori,Megumi Ishiguro,Takashi Okuyama,Akihiro Ohuchi,Shinobu Ohnuma,Kazuhiro Sakamoto,Tamotsu Sugai,Kenji Katsumata,Hiro-o Matsushita,Hiro-o Yamano,Keisuke Nakai,Toshio Uraoka,Naohiko Akimoto,Hirotoshi Kobayashi,Yoichi Ajioka,Kenichi Sugihara,Hideki Ueno
DOI: https://doi.org/10.14309/ajg.0000000000002879
2024-06-14
The American Journal of Gastroenterology
Abstract:Introduction: There is considerable concern about whether endoscopic resection (ER) prior to additional surgery (AS) for T1 colorectal cancer (CRC) has oncologically potential adverse effects. Therefore, this study aimed to compare the long-term outcomes, including overall survival (OS), of patients treated with AS after ER versus primary surgery (PS) for T1 CRC using a propensity score-matched analysis from a large observational study. Methods: This study investigated 6105 patients with T1 CRC treated with either ER or surgical resection between 2009 and 2016 at 27 high-volume Japanese institutions, with those undergoing surgery alone included in the PS group and those undergoing AS after ER included in the AS group. Propensity score matching was used for long-term outcomes of mortality and recurrence analysis. Results: After propensity score matching, 1219 of 2438 patients were identified in each group. The 5-year OS rates in the AS and PS groups were 97.1% and 96.0%, respectively (hazard ratio: 0.72, 95% confidence interval [CI]: 0.49–1.08), indicating the non-inferiority of the AS group. Moreover, 32 patients (2.6%) in the AS group and 24 (2.0%) in the PS group had recurrences, with no significant difference between the two groups (odds ratio: 1.34, 95% CI: 0.76–2.40, p = 0.344). Discussion: ER prior to AS for T1 CRC had no adverse effect on patients' long-term outcomes, including the 5-year OS rate. ER is a viable first-line treatment option for endoscopically resectable T1 CRC.
gastroenterology & hepatology